•  
sterna biologicals home

Clinical Trials

Sterna biologicals conducts clinical trials to advance its development pipeline. Our lead compound, SB010 for moderate and severe Th2-driven asthma, will imminently commence clinical trials. We expect SB011 for atopic dermatitis to start trials in 2012.


CompoundIndicationPhaseDescriptionStatusFurther Details
SB010 Asthma

I

Single dose

ongoing

Press Release (07-NOV-2011)

I

Multiple dose

filed

I

Safety in asthmatics

filed


We also report results of registered clinical trials to www.clinicaltrials.gov.

© sterna biologicals GmbH & Co. KG • Biomedizinisches Forschungszentrum (BMFZ) • Hans-Meerwein-Straße 2 • D-35043 Marburg